NeuroSense Advances Plans For Early Commercialization Of Groundbreaking ALS Treatment In Canada, Provides Further Updates; Dossier Submission Planned For Q2 2025; Regulatory Decision Expected By Q1 2026; Estimated Potential Market Opportunity: Peak Of $100M-$150M In Annual Revenue

Benzinga · 10/15 13:24
  • Dossier submission planned for Q2 2025; regulatory decision expected by Q1 2026
  • Estimated potential market opportunity: peak of $100M to $150M in annual revenue
  • Company aims to expand approval efforts to additional global markets

CAMBRIDGE, Mass., Oct. 15, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, provided a further update on its plans to file for early commercialization approval for PrimeC under Health Canada's Notice of Compliance with Conditions (NOC/c) policy. This submission is based on promising results from the Company's Phase 2b ALS PARADIGM clinical trial, supported by additional clinical and preclinical data.